And big pharma has jumped on it.
Having already processed more than a half billion redactions, ClinGenuity clearly has unsurpassed experience in this critical area, said
"We're seeing significant growth in the market due to our unique redaction technology, workflow and service in addition to our other services and technologies," said Kleeman. "Our clients are some of the largest and most well-respected pharmaceutical companies globally, as well as several of the founding members of
TransCelerate BioPharma is a nonprofit organization founded in 2012 to improve people's health worldwide by accelerating and simplifying the research and development of innovative new therapies and medicines. Members include some of the largest pharmaceutical companies in the world.
Of critical importance to pharma is determining how best to react to and be compliant with both external clinical trial transparency mandates such as
However, prior to complying with transparency and disclosure initiatives and providing these documents to the public, sensitive personal and patient-protected information must first be accurately identified and securely redacted from regulatory documents, he added.
An average document for disclosure, or Clinical Study Report, is about 10,000 pages. Considering there are approximately 600 words per page, that's an average of six million words per study report. Larger pharmaceutical companies doing the minimum to be compliant with Policy 70 would typically need to redact a minimum of 25 clinical study reports per year, or roughly 150 million words each and every year, said Kleeman.
"Finding names, email addresses, patient ID numbers and other sensitive information is like looking for a needle in a haystack," he said. "It's simply unfair to ask a team of humans from a standard Contract Research Organization (CRO) to perform this task accurately. An average CRO does not have intelligent tools to assist the pharma industry in this critically- important task."
ClinGenuity's Redaction Management Service, the pharmaceutical industry's only automated solution, solves these problems by combining artificial intelligence with domain expert, clinically-trained quality control reviewers using proprietary secure tools that assist in managing workflow and rules associated with the transparency initiatives.
"Almost every client we've worked with attempted manual solutions, but quickly found that there were accidental disclosures of sensitive information." said Kleeman. "Our model is to manage the process through the use of intelligent automation that ties rules between automation and human review so that the common failures in consistency and accuracy are alleviated."
ClinGenuity is fast becoming the pharmaceutical industry's gold standard for transparency and disclosure.
"Simply put, we are the most accurate and efficient solution, and as a result we greatly reduce the risk of accidental disclosure and the liability that goes along with such a mistake for our valued clients," said Kleeman. "It's hard to believe, but our competition is sometimes as basic and outdated as humans armed with black markers. We are excited to be such an integral part of this new era of transparency in the pharmaceutical industry, and are proud to assist our clients in this most critical endeavor."
For more information on ClinGenuity, go to http://www.clingenuity.com or call (513) 239-6918.
Phone: (513) 239-6918
Read the full story at http://www.prweb.com/releases/2014/07/prweb12056089.htm
Most Popular Stories
- Alabama House Speaker Arrested on Felony Ethics Charges
- Microsoft's Cloud Platform Shines
- 'Fury' Blows 'Gone Girl' Out of the Box Office
- Turkey to Help Kurds Reach Fight in Kobani
- ISIS Seeks to Expand Terror War
- German Intelligence Blames Ukraine Rebels for MH17
- Perez Leads Push for Obama's Job Proposals
- 2016 Camaro Shrinks, Moves to Caddy Platform
- New Effort to Ban Child Labor From Tobacco Farms
- Prius Drivers Battle Stereotypes